Skip to content
Triangle logo TriangleGet started
← Study library

NCT02601209 · REGISTRY CONDITION SEARCH

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1, PHASE2
Status at capture
TERMINATED
Registry last update
2022-08-23

This phase I/II trial studies the side effects and best dose of sapanisertib and to see how well it works compared to pazopanib hydrochloride in treating patients with sarcoma that is too large to be removed (locally advanced) or has spread to other areas of the body (metastatic). Sapanisertib and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Phase I Participants With Dose-Limiting Toxicity Events (Phase I)

→

outcome · POSTED

Progression-free Survival (PFS) (Phase II Analysis Group 2 - Initial Treatment Period)

→

outcome · POSTED

The Number of Patients Who Experienced Grade 3+ Adverse Events (Phase II Analysis Group 2 - Initial Treatment Period)

→

outcome · POSTED

Tumor Response (Complete Response [CR], Partial Response [PR], Stable Disease [SD], and Progressive Disease [PD])(Phase II Analysis Group 2 - Initial Treatment Period)

→

outcome · POSTED

Duration of Response (Phase II Analysis Group 2 - Initial Treatment Period)

→

outcome · POSTED

Number of Patients Having CR, PR, or SD at 6 Months (Phase II Analysis Group 2 - Initial Treatment Period)

→

outcome · POSTED

Time to Progression (TTP) (Phase II Analysis Group 2 - Initial Treatment Period)

→

outcome · POSTED

Overall Survival (OS) (Phase II Analysis Group 2 - Initial Treatment Period)

→

outcome · NOT POSTED

Progression-free Survival (PFS) (Phase II)

→

outcome · NOT POSTED

Duration of Response in Crossover Patients (Phase II)

→

outcome · NOT POSTED

Time to Progression (TTP) in Crossover Patients (Phase II)

→

outcome · NOT POSTED

Overall Survival (OS) in Crossover Patients (Phase II)

→

outcome · NOT POSTED

Cohort-specific Evaluation of 4-month Clinical Benefit Rate (CBR) (Phase II, Analysis Group II)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Patients must have slides available for submission to central pathology review; this review is mandatory prior to registration to confirm eligibility and proper cohort assignment * HISTOLOGIC COHORT 1: Undifferentiated pleomorphic sarcoma (includes: malignant fibrous histiocytoma, myxofibrosarcoma, high grade sarcoma not otherwise specified \[NOS\]) * HISTOLOGIC COHORT 2: Leiomyosarcoma (either uterine or extra-uterine) * HISTOLOGIC COHORT 3: Other (either malignant peripheral nerve sheath tumor or synovial sarcoma); during the phase II portion of the study, enrollment will be limited to maximum of 25 patients in this cohort * Note that the phase I is limited to the histologic subtypes listed above; since patients will be enrolling onto dose cohorts during the phase I, they will not enroll onto specific histologic cohorts, although the histologic subtype informed will be collected during patient enrollment * Histologic documentation: Eligible patients must have histopathologically confirmed sarcoma of one of the subtypes listed, by central review * Locally advanced or metastatic disease; locally advanced disease is defined as disease not amenable to local therapy such as surgery and/or radiation * Measurable disease * Progression on at least one prior systemic chemotherapy for advanced, unresectable or metastatic disease; prior adjuvant or neoadjuvant therapy is not included as prior systemic chemotherapy unless treatment occurred within the 6 months prior to study enrollment * There is no limit to the number of prior lines of treatment a patient has received * No treatment with biological therapy, immunotherapy, chemotherapy, investigational agent for malignancy, or radiation =\< 28 days before study registration; no treatment with nitrosourea or mitomycin =\< 42 days before study registration * No treatment with radiation therapy =\< 28 days before study registration * Patients should have resolution of any toxic effects of prior therapy (except alopecia) to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, grade 1 or less * Prior treatment with pazopanib or any phosphoinositide 3-kinase (PI3K), mTOR, protein kinase B (AKT), or dual PI3K/mTOR complex (CREB regulated transcription coactivator \[TORC\]1/TORC2) inhibitors will be prohibited * Not pregnant and not nursing; because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown and an agent that has known genotoxic, mutagenic and teratogenic effects; therefore, for women of childbearing potential only, a negative pregnancy test done =\< 7 days prior to registration is required * Eastern Cooperative Oncology Group (ECOG) performance status =\< 1 * Patient history: patients who have any of the following are NOT eligible: * Central nervous system (CNS): Symptomatic, untreated, or uncontrolled brain metastases present * Heme: Active bleeding or bleeding diathesis * Gastrointestinal (GI): * Abdominal fistula, GI perforation, or intra-abdominal abscess within 28 days prior to registration * Acute GI bleed within 28 days of registration * Diabetes mellitus: Patients with diabetes mellitus with inadequate control, based on either a glycosylated hemoglobin (Hgb A1c) of \> 7.0 or fasting blood glucose above or equal to 130 mg/dL * Cardiac and vascular disorders: * History of congenital long QT syndrome or torsades de pointes * Any arrhythmia that is currently not rate-controlled (rate between 60 and 100) * Prolongation of corrected QT interval via Fridericia's formula (QTcF) \> 480 msec * Ongoing unstable angina * Symptomatic peripheral vascular disease * Arterial thrombosis within 28 days of registration including transient ischemic attack (TIA), cerebrovascular accident (CVA), myocardial infarction (MI) * Patients with deep vein thrombosis (DVT) or pulmonary embolism (PE) must be on a stable dose of anticoagulation for 14 days prior to registration * Uncontrolled hypertension, defined as blood pressure (BP) \> 140/90 * Multi gated acquisition scan (MUGA) with ejection fraction (EF), 50% or echocardiogram (echo) with low EF * Class III or IV congestive heart failure (CHF) within 28 days of registration * Chronic concomitant treatment with proton pump inhibitors must discontinue the drug for 7 days prior to registration on the study * Chronic concomitant treatment with strong inhibitors of CYP3A4 inhibitors must discontinue the drug for 14 days prior to registration on the study * Chronic concomitant treatment with strong CYP3A4 inducers is not allowed; patients must discontinue the drug 14 days prior to the start of study treatment * Absolute neutrophil count (ANC) \>= 1,500/mm\^3 * Platelet count \>= 100,000/mm\^3 * Creatinine =\< 1.5 x upper limit of normal (ULN) * Total bilirubin =\< 1.5 x upper limit of normal (ULN); unless patient has Gilbert disease * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 3 x upper limit of normal (ULN); if liver metastases, =\< 5 x upper limit of normal (ULN) * Urine protein creatinine (UPC) =\< 1; if UPC \>= 1, then a 24-hour urine protein must be assessed; eligible patients must have a 24-hour urine protein value \< 1 g/L * Thyroid stimulating hormone (TSH) within normal limits (WNL); supplementation is acceptable to achieve a TSH WNL; in patients with abnormal TSH however if the Free T4 is normal and patient is clinically euthyroid, patient is eligible
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive sapanisertib as in Phase I. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: Sapanisertib
    label
    Arm I (sapanisertib)
    type
    EXPERIMENTAL
  2. description
    Patients receive pazopanib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm I.
    intervention Names
    1. Drug: Pazopanib
    2. Drug: Pazopanib Hydrochloride
    label
    Arm II (pazopanib hydrochloride)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Arm II (pazopanib hydrochloride)
    description
    Given PO
    name
    Pazopanib
    other Names
    1. GW786034
    type
    DRUG
  2. arm Group Labels
    1. Arm II (pazopanib hydrochloride)
    description
    Given PO
    name
    Pazopanib Hydrochloride
    other Names
    1. GW786034B
    2. Votrient
    type
    DRUG
  3. arm Group Labels
    1. Arm I (sapanisertib)
    description
    Given PO
    name
    Sapanisertib
    other Names
    1. INK-128
    2. INK128
    3. MLN-0128
    4. MLN0128
    5. TAK-228
    type
    DRUG
Study design
allocation
RANDOMIZED
intervention Model
CROSSOVER
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
151
type
ACTUAL
Registered outcome plans (not posted results)
other Outcomes
  1. description
    Defined as either disease progression or death (in cases where patients have died without evidence of disease progression) in crossover patients.
    measure
    Progression-free Survival (PFS) (Phase II)
    time Frame
    Up to 2 years
  2. description
    Will be analyzed using Kaplan-Meier methodology.
    measure
    Duration of Response in Crossover Patients (Phase II)
    time Frame
    Time between each patient's best tumor response and progression>>> (or date of last disease assessment for patients who die without progression or are lost to follow-up), assessed up to 2 years
  3. description
    Kaplan-Meier methodology will be used to estimate the distribution of\>\>\> TTP.
    measure
    Time to Progression (TTP) in Crossover Patients (Phase II)
    time Frame
    Time between date the patient initiated sapanisertib and disease progression, assessed up to 2 years
  4. description
    Kaplan-Meier methodology will be used to estimate the distribution of\>\>\> OS.
    measure
    Overall Survival (OS) in Crossover Patients (Phase II)
    time Frame
    Time between date the patient initiated sapanisertib and death due to any cause (or last contact for surviving patients and those lost to follow-up), assessed up to 2 years
  5. description
    Analyses will be exploratory in nature.
    measure
    Cohort-specific Evaluation of 4-month Clinical Benefit Rate (CBR) (Phase II, Analysis Group II)
    time Frame
    4 months
primary Outcomes
  1. description
    The Maximum Tolerated Dose (MTD) of sapanisertib (MLN0128) is defined as the dose level below the lowest dose that induces dose-limiting toxicity (DLT) in at least one-third of patients graded according to NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Dose-limiting toxicities include non-hematologic events graded 3 or higher and deemed at least possibly related to treatment. The number of patients reporting a dose-limiting event is reported.
    measure
    Number of Phase I Participants With Dose-Limiting Toxicity Events (Phase I)
    time Frame
    28 days
  2. description
    Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and an upper confidence boundary from a 1-sided, 85% confidence interval are estimated using the Kaplan-Meier methods.
    measure
    Progression-free Survival (PFS) (Phase II Analysis Group 2 - Initial Treatment Period)
    time Frame
    Up to 2 years
secondary Outcomes
  1. description
    The number of patients who experienced grade 3+ adverse events for Phase II Analysis Group 2 for the initial treatment period is reported below.
    measure
    The Number of Patients Who Experienced Grade 3+ Adverse Events (Phase II Analysis Group 2 - Initial Treatment Period)
    time Frame
    Up to 4 months
  2. description
    The frequencies (and percentages) of tumor response categories (CR, PR, SD, PD) will be summarized for Phase II Analysis Group 2. Complete Response (CR): All of the following must be true: a. Disappearance of all target lesions. b. Each target lymph node must have reduction in short axis to \< 1.0 cm. Partial Response (PR): At least a 30% decrease in PBSD taking as reference the BSD. Progression (PD): At least one of the following must be true: a. At least one new malignant lesion, b. At least a 20% increase in PBSD. c. PD via FDG-PET imaging. d. unequivocal progression of existing non-target lesions and non-target lymph nodes. e. symptomatic deterioration. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD taking as reference the MSD.
    measure
    Tumor Response (Complete Response [CR], Partial Response [PR], Stable Disease [SD], and Progressive Disease [PD])(Phase II Analysis Group 2 - Initial Treatment Period)
    time Frame
    Up to 2 years
  3. description
    Duration of response is defined as the time between each patient's best tumor response and progression (or date of last disease assessment for patients who die without progression or are lost to follow-up). Complete Response (CR): All of the following must be true: a. Disappearance of all target lesions. b. Each target lymph node must have reduction in short axis to \< 1.0 cm. Partial Response (PR): At least a 30% decrease in PBSD taking as reference the BSD.
    measure
    Duration of Response (Phase II Analysis Group 2 - Initial Treatment Period)
    time Frame
    Time between each patient's best tumor response and progression(or date of last disease assessment for patients who die without progression or are lost to follow-up), assessed up to 2 years
  4. description
    Will be defined as the number of patients having either complete response (CR), partial response (PR), or stable disease for at least 6 months after starting treatment. The frequencies and rates of tumor response categories (CR, PR, SD, PD, and too early/not evaluated) will be summarized by dose cohort and treatment arm. Complete Response (CR): All of the following must be true: a. Disappearance of all target lesions. b. Each target lymph node must have reduction in short axis to \< 1.0 cm. Partial Response (PR): At least a 30% decrease in PBSD taking as reference the BSD. Progression (PD): At least one of the following must be true: a. At least one new malignant lesion,b. At least a 20% increase in PBSD. c. PD via FDG-PET imaging. d. unequivocal progression of existing non-target lesions and non-target lymph nodes. e. symptomatic deterioration. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD taking as reference the MSD.
    measure
    Number of Patients Having CR, PR, or SD at 6 Months (Phase II Analysis Group 2 - Initial Treatment Period)
    time Frame
    Up to 6 months
  5. description
    Time to progression is defined as the time between randomization and disease progression. Kaplan-Meier methodology will be used to estimate the distribution of TTP. Progression (PD): At least one of the following must be true: a. At least one new malignant lesion,b. At least a 20% increase in PBSD. c. PD via FDG-PET imaging. d. unequivocal progression of existing non-target lesions and non-target lymph nodes. e. Symptomatic deterioration.
    measure
    Time to Progression (TTP) (Phase II Analysis Group 2 - Initial Treatment Period)
    time Frame
    Time between randomization and disease progression, assessed up to 2 years
  6. description
    Overall survival (OS) (Phase II Analysis Group 2 - Initial Treatment Period). Kaplan-Meier methodology will be used to estimate the distribution of OS.
    measure
    Overall Survival (OS) (Phase II Analysis Group 2 - Initial Treatment Period)
    time Frame
    Time between randomization and death due to any cause (or last contact for surviving patients and those lost to follow-up), assessed up to 2 years
Full study description
brief Summary
This phase I/II trial studies the side effects and best dose of sapanisertib and to see how well it works compared to pazopanib hydrochloride in treating patients with sarcoma that is too large to be removed (locally advanced) or has spread to other areas of the body (metastatic). Sapanisertib and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
detailed Description
PRIMARY OBJECTIVES: I. To determine the safety and maximum tolerable dose of sapanisertib (MLN0128 \[TAK-228\]) within this patient population. (Phase I) II. To determine the differences in progression-free survival (PFS) in patients with sarcoma who receive MLN0128 (TAK-228) as compared to pazopanib (pazopanib hydrochloride). (Phase II) SECONDARY OBJECTIVES: I. To evaluate adverse events. (Phase I/II) II. To evaluate overall response rate (ORR), clinical benefit rate (CBR), and duration of response (DOR). (Phase I/II) III. To evaluate time to progression (TTP) and overall survival (OS). (Phase I/II) EXPLORATORY OBJECTIVES: I. To evaluate PFS and secondary endpoints within patients crossing over to MLN0128 (TAK-228), upon disease progression during treatment with pazopanib. (Phase II) II. To evaluate the 4 month CBR observed within patients treated with MLN0128 (TAK-228) and grouped by histologically defined cohorts. (Phase II) OUTLINE: This is a phase I, dose-escalation study, followed by a randomized phase II study. PHASE I: Patients receive sapanisertib orally (PO) on days 1, 8, 15, and 22 in the absence of disease progression or unacceptable toxicity. PHASE II: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive sapanisertib as in Phase I. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive pazopanib hydrochloride PO once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm I. After completion of study treatment, patients are followed up at 4 weeks and then every 6 months for 2 years.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-308ad8be2c4828eb27cc
      requested nct id
      NCT02601209
      primary nct id
      NCT02601209
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      21b84c01b125d04528c86b8a2e80343ce07b200dcda51c3b1328a536daf43d89
      payload sha256
      c79f1413fea5e377c215de182f6caea4d84d6b410006a7ac67bd94f9c6964504
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-308ad8be2c4828eb27cc
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02601209
      occurrences
      1. context exact
        NCT02601209
        end
        11
        exact text
        NCT02601209
        start
        0
      offset unit
      unicode_code_points
      query cond
      Uterine Sarcoma
      query disease state id
      ds-uterine-sarcoma
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-uterine-sarcoma-000.json
      source file sha256
      21b84c01b125d04528c86b8a2e80343ce07b200dcda51c3b1328a536daf43d89
      source json pointer
      /studies/19/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      99d723b932594ce74890d2fd6d0c1fbd84826ea44bf59319f204dbc3fb2bbcbf
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-b4482a8334eda8f82e3c
      requested nct id
      NCT02601209
      primary nct id
      NCT02601209
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      bac1ec1281373ee4e9e39781fe34b553efe52105d6d2ce39d01500a3a6db7b66
      payload sha256
      cfd1c6ed897db57222d60f63aeca81e6fe2ccbf5ee233297139eaef2c95d7da2
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-b4482a8334eda8f82e3c
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02601209
      occurrences
      1. context exact
        NCT02601209
        end
        11
        exact text
        NCT02601209
        start
        0
      offset unit
      unicode_code_points
      query cond
      Histiocytoma
      query disease state id
      ds-histiocytoma
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-histiocytoma-000.json
      source file sha256
      bac1ec1281373ee4e9e39781fe34b553efe52105d6d2ce39d01500a3a6db7b66
      source json pointer
      /studies/8/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      99d723b932594ce74890d2fd6d0c1fbd84826ea44bf59319f204dbc3fb2bbcbf

    Preserved source evidence · Not medical advice